Donald A. Kalkofen is CFO at Protagonist Therapeutics, Inc (PTGX). They have made 1 open-market trade across 1 company since 2019, most recently 2022-02-15.
CIK 0001771066
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $6K since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PTGX | 18,521 | $2.7M |
Shares reported on the most recent Form 4, priced at the 2022-02-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PTGX | BUY | 2019-12-03 | 2019-12-03 | $5.10 | $6K | +33.2% | +26.0% | +44.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.